<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01759836</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-PC2012002</org_study_id>
    <nct_id>NCT01759836</nct_id>
  </id_info>
  <brief_title>Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer</brief_title>
  <official_title>A Randomized Double Blind, Placebo-controlled Study Determining the Role of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biochemical recurrence develops in approximately 30-40% of men with locally advanced prostate
      cancer who undergo radical prostatectomy. To date, the effect of statins on prostate cancer
      recurrence has been investigated in several retrospective studies with inconsistent results.
      The purpose of this study is to determine the impact of statin on biochemical recurrence
      after radical prostatectomy for locally advanced prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Estimated Enrollment: 354

      Study start date: October 2012

      Estimated Study Completion Date: October 2015

      Statin Group: Treatment with Atorvastatin 20mg daily after radical prostatectomy during 1
      year.

      Control Group: Treatment with Placebo daily after radical prostatectomy during 1 year.

      Follow up: every 3 months for the first year. Check PSA, Total/LDL-cholesterol and
      Triglyceride.

      Primary End Point Rate of Biochemical recurrence

      Secondary End Point Clinical progression of prostate cancer Change of Total/LDL- cholesterol
      and Triglycerides 5 year-Biochemical recurrence free survival
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of biochemical recurrence</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical recurrence free survival</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical progression-free survival</measure>
    <time_frame>Five years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 20mg daily for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20mg</intervention_name>
    <description>Atorvastatin 20mg daily for 1 year</description>
    <arm_group_label>Atorvastatin 20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have correspond to one of the following three pathologic criteria.

             A. Gleason scores 8 or greater B. Positive resection margin C. pT3-T4

          2. Patients must have pathologically adenocarcinoma

          3. Patients must be enrolled within 60 days after radical prostatectomy

          4. Patients must be able to provide written informed consent

        Exclusion Criteria:

          1. Patients who have received neoadjuvant androgen deprivation therapy

          2. Patients who have the participation of other clinical trial within the past 3 months

          3. Patients who have treated with statin

          4. Patients who have lymph node metastasis or distant metastasis

          5. Patients who have 10 year risk of cardiovascular disease over 10% based on NCEP ATP
             III guideline.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choung-Soo Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology,Asan Medical Center, Seoul</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Choung-Soo Kim, MD</last_name>
    <phone>82-2-3010-3734</phone>
    <email>cskim@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>In Gab Jeong, MD</last_name>
    <phone>82-2-3010-5892</phone>
    <email>igjeong@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Choung-Soo Kim, MD</last_name>
      <phone>82-2-3010-3734</phone>
      <email>cskim@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>In Gab Jeong, MD</last_name>
      <phone>82-2-3010-5892</phone>
      <email>igjeong@amc.seoul.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Choung-soo Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2013</study_first_submitted>
  <study_first_submitted_qc>January 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <last_update_submitted>January 9, 2013</last_update_submitted>
  <last_update_submitted_qc>January 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Choung-Soo Kim</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Prostatectomy</keyword>
  <keyword>Statins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

